Stock Events

Pharming N.V. 

€0.78
240
+€0.01+1.04% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
537.07M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.19
0.01
0.2
0.4
Expected EPS
N/A
Actual EPS
-0.19

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHGN.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Carlisle Companies
CSL
Mkt Cap20.49B
CSL Behring competes in the plasma-derived and recombinant therapeutic products space, similar to Pharming's focus on protein replacement therapies.
Takeda Pharmaceutical
TAK
Mkt Cap42.54B
Takeda Pharmaceutical Company has a strong presence in the rare diseases market, directly competing with Pharming's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap16.14B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing with Pharming's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other rare diseases, presenting competition in the rare disease market.
AMGEN
AMGN
Mkt Cap177.47B
Amgen operates in the biotechnology field focusing on rare diseases among other areas, making it a competitor in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals is involved in developing and marketing products for rare diseases, among other areas, competing with Pharming.
GSK
GSK
Mkt Cap81.16B
GlaxoSmithKline has a diverse portfolio including treatments for rare diseases, competing with Pharming in various therapeutic areas.
Pfizer
PFE
Mkt Cap163.88B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the pharmaceutical and biotech industry.
Sanofi
SNY
Mkt Cap130B
Sanofi focuses on rare diseases, multiple sclerosis, and oncology, among others, competing with Pharming in the rare disease space.

About

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Show more...
CEO
Dr. Sijmen de Vries M.B.A., M.D.
Employees
382
Country
NL
ISIN
NL0010391025
WKN
000A1H65A

Listings